Show simple item record

dc.contributor.authorMcGowan, B
dc.contributor.authorBennett, K
dc.contributor.authorBarry, M
dc.contributor.authorOwens, M
dc.contributor.authorO'Connor, M
dc.date.accessioned2013-10-03T13:52:31Z
dc.date.available2013-10-03T13:52:31Z
dc.date.issued2009-03
dc.identifier.citationAn analysis of the utilisation and expenditure of medicines dispensed for the management of severe asthma. 2009, 102 (3):73-6 Ir Med Jen_GB
dc.identifier.issn0332-3102
dc.identifier.pmid19489193
dc.identifier.urihttp://hdl.handle.net/10147/302664
dc.description.abstractThere are approximately 6,300 people in Ireland with a diagnosis of Chronic Obstructive Pulmonary Disease (COPD) and with a fast growing elderly population the incidence of COPD is likely to increase. This study examines the prescribing patterns of medicines dispensed for the management Asthma/COPD in patients over the age of 35 years using the HSE-Primary Care Reimbursement Services (PCRS) prescribing databases. The HSE-PCRS pharmacy claims data, which covers all those over 70 years of age and means tested for those less than 70 years, was analysed for the years 2005/2006. Approximately 26,548 (17.9%) of patients who were prescribed a respiratory drug received inhaled short-acting beta2 agonists in combination with a regular standard-dose inhaled corticosteroid. A further 5,044 (3.4%) were also prescribed a regular inhaled long-acting beta2 agonist (salmeterol or formoterol). A total of 2506 patients (6.2%) on combination therapy were co-prescribed four different anti-asthmatic treatments inclusive of oral prednisolone. A small proportion of the patients prescribed a respiratory drug were co-prescribed nicotine replacement therapy (n = 5177, 3.5%). In total there were 9,728 (6.2%) patients prescribed a mucolytic drug in combination with a respiratory drug and the rate of co-prescribing with antibiotics was 22%. COPD is a debilitating disease that is primarily caused by smoking and is therefore largely preventable. The HSE-PCRS pharmacy claims data is a valuable tool for helping to assess the burden of this disease in the Irish context.
dc.language.isoenen
dc.rightsArchived with thanks to Irish medical journalen_GB
dc.subjectASTHMAen_GB
dc.subjectMEDICATION MANAGEMENTen_GB
dc.subject.meshAdrenal Cortex Hormones
dc.subject.meshAdrenergic beta-Agonists
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAlbuterol
dc.subject.meshAnti-Asthmatic Agents
dc.subject.meshAsthma
dc.subject.meshBronchodilator Agents
dc.subject.meshDrug Therapy, Combination
dc.subject.meshEthanolamines
dc.subject.meshFemale
dc.subject.meshHealth Expenditures
dc.subject.meshHealth Services
dc.subject.meshHumans
dc.subject.meshIncidence
dc.subject.meshIreland
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshPhysician's Practice Patterns
dc.subject.meshPulmonary Disease, Chronic Obstructive
dc.titleAn analysis of the utilisation and expenditure of medicines dispensed for the management of severe asthma.en_GB
dc.typeArticleen
dc.contributor.departmentDepartment of Pharmacology and Therapeutics, Trinity Centre for Health Sciences, St James's Hospital, James's St, Dublin 8. mcgowab@tcd.ieen_GB
dc.identifier.journalIrish medical journalen_GB
refterms.dateFOA2018-08-23T08:07:18Z
html.description.abstractThere are approximately 6,300 people in Ireland with a diagnosis of Chronic Obstructive Pulmonary Disease (COPD) and with a fast growing elderly population the incidence of COPD is likely to increase. This study examines the prescribing patterns of medicines dispensed for the management Asthma/COPD in patients over the age of 35 years using the HSE-Primary Care Reimbursement Services (PCRS) prescribing databases. The HSE-PCRS pharmacy claims data, which covers all those over 70 years of age and means tested for those less than 70 years, was analysed for the years 2005/2006. Approximately 26,548 (17.9%) of patients who were prescribed a respiratory drug received inhaled short-acting beta2 agonists in combination with a regular standard-dose inhaled corticosteroid. A further 5,044 (3.4%) were also prescribed a regular inhaled long-acting beta2 agonist (salmeterol or formoterol). A total of 2506 patients (6.2%) on combination therapy were co-prescribed four different anti-asthmatic treatments inclusive of oral prednisolone. A small proportion of the patients prescribed a respiratory drug were co-prescribed nicotine replacement therapy (n = 5177, 3.5%). In total there were 9,728 (6.2%) patients prescribed a mucolytic drug in combination with a respiratory drug and the rate of co-prescribing with antibiotics was 22%. COPD is a debilitating disease that is primarily caused by smoking and is therefore largely preventable. The HSE-PCRS pharmacy claims data is a valuable tool for helping to assess the burden of this disease in the Irish context.


Files in this item

Thumbnail
Name:
Article5152.pdf
Size:
10.33Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record